Completing the arc: Targeted inhibition of RET in medullary thyroid cancer

Journal of Clinical Oncology

Volumn 30, Issue 2, 2012, Pages 200-202

  Houvras, Yariv ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; GEFITINIB; LYSINE; METHIONINE; NEUROPEPTIDE; PLACEBO; PROTEIN RET; VALINE; VANDETANIB;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER SURVIVAL; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG TARGETING; GENE MUTATION; HUMAN; HYPERTENSION; MOLECULARLY TARGETED THERAPY; MULTIPLE ENDOCRINE NEOPLASIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; SOMATIC MUTATION; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT OUTCOME;

FEMALE; HUMANS; MALE; PIPERIDINES; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84855615605     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.7639     Document Type: Article

References (17)

1. Wells SA Jr, Robinson BG, Gagel RF, et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, doubleblind phase III trial. J Clin Oncol 30:134-141, 2012
2. Kloos RT, Eng C, Evans DB, et al: Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19:565-612, 2009
3. Moura MM, Cavaco BM, Pinto AE, et al: Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100:1777-1783, 2009
4. Plaza-Menacho I, Burzynski GM, de Groot JW, et al: Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 22:627-636, 2006 (Pubitemid 44602269)
5. Amiel J, Sproat-Emison E, Garcia-Barcelo M, et al: Hirschsprung disease, associated syndromes and genetics: A review. J Med Genet 45:1-14, 2008 (Pubitemid 351158152)
6. Ciampi R, Nikiforov YE: RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148:936-941, 2007
7. Nikiforov YE, Koshoffer A, Nikiforova M, et al: Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 18:6330-6334, 1999
8. Santoro M, Chiappetta G, Cerrato A, et al: Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/ PTC1 oncogene in transgenic mice. Oncogene 12:1821-1826, 1996 (Pubitemid 26146307)
9. Carlomagno F, Vitagliano D, Guida T, et al: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290, 2002 (Pubitemid 36025251)
10. AstraZeneca: Vandetanib (VD6474) tablets: Oncologic Drugs Advisory Committee (ODAC) meeting briefing document, December 2, 2010. http://www .fda.gov/downloads/AdvisoryCommittees/Committees MeetingMaterials/Drugs/ OncologicDrugsAdvisory Committee/UCM235092.pdf
11. Vitagliano D, De Falco V, Tamburrino A, et al: The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer 18:1-11, 2011
12. Pennell NA, Daniels GH, Haddad RI, et al: A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323, 2008 (Pubitemid 351415790)
13. Wells SA Jr, Gosnell JE, Gagel RF, et al: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767-772, 2010
14. Carlomagno F, Guida T, Anaganti S, et al: Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 23:6056-6063, 2004 (Pubitemid 39178858)
15. Carlomagno F, Guida T, Anaganti S, et al: Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474. EndocrRelat Cancer 16:233-241, 2009
16. Knowles PP, Murray-Rust J, Kjaer S, et al: Structure and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577-33587, 2006 (Pubitemid 46036738)
17. Donis-Keller H, Dou S, Chi D, et al: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856, 1993 (Pubitemid 23216611)